

Neue Therapiestrategien gegen antibiotikaresistente Bakterienstämme

## Die Behandlung komplexer Infektionen in der Intensivmedizin

Nouvelles stratégies dans la prise en charge:

### Infections complexes en médecine intensive

---

#### Literatur / Référence

1. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302(21):2323-9.
2. Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med. 2013;369(9):840-51.
3. Que YA, Delodder F, Guessous I, Graf R, Bain M, Calandra T, et al. Pancreatic stone protein as an early biomarker predicting mortality in a prospective cohort of patients with sepsis requiring ICU management. Crit Care. 2012;16(4):R114.
4. Boucher HW, Talbot GH, Benjamin DK, Jr., Bradley J, Guidos RJ, Jones RN, et al. 10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis. 2013;56(12):1685-94.
5. Spellberg B, Bartlett JG, Gilbert DN. The future of antibiotics and resistance. N Engl J Med. 2013;368(4):299-302.

6. Drusano GL, Lodise TP. Saving lives with optimal antimicrobial chemotherapy. *Clin Infect Dis.* 2013;56(2):245-7.
7. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. *Crit Care Med.* 2009;37(3):840-51; quiz 59.
8. Chant C, Leung A, Friedrich JO. Optimal dosing of antibiotics in critically ill patients by using continuous/extended infusions: a systematic review and meta-analysis. *Crit Care.* 2013;17(6):R279.
9. Dulhunty JM, Roberts JA, Davis JS, Webb SA, Bellomo R, Gomersall C, et al. Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. *Clin Infect Dis.* 2013;56(2):236-44.
10. Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. *Clin Pharmacokinet.* 2010;49(1):1-16.
11. Clavel M. Indications des aérosols d'antibiotiques chez les patients sous ventilation mécanique. *Réanimation.* 2014;23:271-7.
12. Lu Q, Yang J, Liu Z, Gutierrez C, Aymard G, Rouby JJ, et al. Nebulized ceftazidime and amikacin in ventilator-associated pneumonia caused by *Pseudomonas aeruginosa*. *Am J Respir Crit Care Med.* 2011;184(1):106-15.

13. Lu Q, Luo R, Bodin L, Yang J, Zahr N, Aubry A, et al. Efficacy of high-dose nebulized colistin in ventilator-associated pneumonia caused by multidrug-resistant *Pseudomonas aeruginosa* and *Acinetobacter baumannii*. *Anesthesiology*. 2012;117(6):1335-47.
14. Casadevall A, Dadachova E, Pirofski LA. Passive antibody therapy for infectious diseases. *Nat Rev Microbiol*. 2004;2(9):695-703.
15. Lu Q, Rouby JJ, Laterre PF, Eggimann P, Dugard A, Giamarellos-Bourboulis EJ, et al. Pharmacokinetics and safety of panobacumab: specific adjunctive immunotherapy in critical patients with nosocomial *Pseudomonas aeruginosa* O11 pneumonia. *J Antimicrob Chemother*. 2011;66(5):1110-6.
16. Que YA, Lazar H, Wolff M, Francois B, Laterre PF, Mercier E, et al. Assessment of panobacumab as adjunctive immunotherapy for the treatment of nosocomial *Pseudomonas aeruginosa* pneumonia. *Eur J Clin Microbiol Infect Dis*. 2014.
17. Dublanchet A, Fruciano E. A short history of phage therapy. *Medecine et maladies infectieuses*. 2008;38(8):415-20.
18. Mislin GL, Schalk IJ. Siderophore-dependent iron uptake systems as gates for antibiotic Trojan horse strategies against *Pseudomonas aeruginosa*. *Metallomics: integrated biometal science*. 2014;6(3):408-20.

19. Rouby JJ, Bouhemad B, Monsel A, Brisson H, Arbelot C, Lu Q, et al. Aerosolized antibiotics for ventilator-associated pneumonia: lessons from experimental studies. *Anesthesiology*. 2012;117(6):1364-80.
20. McKenzie C. Antibiotic dosing in critical illness. *J Antimicrob Chemother*. 2011;66 Suppl 2:ii25-31.
21. Schuetz P, Haubitz S, Albrich W, Müller B. Moins, c'est souvent mieux: une antibiothérapie sur mesure grâce au dosage de la procalcitonine. *Forum Med Suisse*. 2012;12(46):887-92.
22. Knoll BM, Mylonakis E. Antibacterial bioagents based on principles of bacteriophage biology: an overview. *Clin Infect Dis*. 2014;58(4):528-34.